BACKGROUND: Cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) is a potentially curative treatment for peritoneal carcinomatosis. OBJECTIVE: The aim of this study was to determine the predictive value of postoperative inflammatory biomarkers in assessing complications after CRS and HIPEC. METHODS: A prospective database of 181 patients, who underwent CRS-HIPEC between March 2014 through April 2018 in the Erasmus MC, was retrospectively analyzed. Postoperative complications were defined according to the serious adverse event (SAE) grading system. Levels of C-reactive protein (CRP) and white blood cell (WBC) count were compared between patients with SAE grade < 3 and SAE grade ≥ 3. The area under the receiver operating characteristic curve (AUC) was calculated for CRP and WBC against SAE ≥ 3 and various intra-abdominal complications. RESULTS: SAE ≥ 3 postoperative complications occurred in 50 patients. From the second until the fifth postoperative day (POD), CRP levels were significantly higher (p = 0.023, p < 0.001, p = 0.002, and p = 0.002, respectively) in these patients. CRP concentrations above 166 mg/L on POD3 (AUC 0.75) and 116 mg/L on POD4 (AUC 0.70) were associated with the highest risk of an SAE ≥ 3. Postoperative WBC levels were not significantly different between patients with SAE < 3 and SAE ≥ 3 complications. CONCLUSION: Data from our hospital suggest that CRP levels that continue to rise after POD2 or that are ≥ 166 mg/L at POD3 or ≥ 116 mg/L at POD4, indicate a considerable risk for developing high-grade SAEs. The cut-off values we found can potentially be used as a threshold for additional diagnostic interventions, after they have been validated in external data.
BACKGROUND: Cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) is a potentially curative treatment for peritoneal carcinomatosis. OBJECTIVE: The aim of this study was to determine the predictive value of postoperative inflammatory biomarkers in assessing complications after CRS and HIPEC. METHODS: A prospective database of 181 patients, who underwent CRS-HIPEC between March 2014 through April 2018 in the Erasmus MC, was retrospectively analyzed. Postoperative complications were defined according to the serious adverse event (SAE) grading system. Levels of C-reactive protein (CRP) and white blood cell (WBC) count were compared between patients with SAE grade < 3 and SAE grade ≥ 3. The area under the receiver operating characteristic curve (AUC) was calculated for CRP and WBC against SAE ≥ 3 and various intra-abdominal complications. RESULTS: SAE ≥ 3 postoperative complications occurred in 50 patients. From the second until the fifth postoperative day (POD), CRP levels were significantly higher (p = 0.023, p < 0.001, p = 0.002, and p = 0.002, respectively) in these patients. CRP concentrations above 166 mg/L on POD3 (AUC 0.75) and 116 mg/L on POD4 (AUC 0.70) were associated with the highest risk of an SAE ≥ 3. Postoperative WBC levels were not significantly different between patients with SAE < 3 and SAE ≥ 3 complications. CONCLUSION: Data from our hospital suggest that CRP levels that continue to rise after POD2 or that are ≥ 166 mg/L at POD3 or ≥ 116 mg/L at POD4, indicate a considerable risk for developing high-grade SAEs. The cut-off values we found can potentially be used as a threshold for additional diagnostic interventions, after they have been validated in external data.
Authors: Philipp Horvath; Stefan Beckert; Florian Struller; Alfred Königsrainer; Ingmar Königsrainer Journal: World J Gastrointest Pharmacol Ther Date: 2016-08-06
Authors: Olivier Glehen; François N Gilly; Florent Boutitie; Jean M Bereder; François Quenet; Lucas Sideris; Baudouin Mansvelt; Gérard Lorimier; Simon Msika; Dominique Elias Journal: Cancer Date: 2010-08-24 Impact factor: 6.860
Authors: Terence C Chua; Brendan J Moran; Paul H Sugarbaker; Edward A Levine; Olivier Glehen; François N Gilly; Dario Baratti; Marcello Deraco; Dominique Elias; Armando Sardi; Winston Liauw; Tristan D Yan; Pedro Barrios; Alberto Gómez Portilla; Ignace H J T de Hingh; Wim P Ceelen; Joerg O Pelz; Pompiliu Piso; Santiago González-Moreno; Kurt Van Der Speeten; David L Morris Journal: J Clin Oncol Date: 2012-05-21 Impact factor: 44.544
Authors: Madalyn G Peters; Edmund K Bartlett; Robert E Roses; Rachel R Kelz; Douglas L Fraker; Giorgos C Karakousis Journal: Ann Surg Oncol Date: 2015-05-27 Impact factor: 5.344
Authors: Edward A Levine; John H Stewart; Perry Shen; Gregory B Russell; Brian L Loggie; Konstantinos I Votanopoulos Journal: J Am Coll Surg Date: 2013-12-21 Impact factor: 6.113
Authors: Sarah L Gans; Jasper J Atema; Susan van Dieren; Bas Groot Koerkamp; Marja A Boermeester Journal: Int J Colorectal Dis Date: 2015-05-03 Impact factor: 2.571
Authors: Maurizio Cardi; Simone Sibio; Francesco Di Marzo; Francesco Lefoche; Claudia d'Agostino; Giovanni Battista Fonsi; Giuseppe La Torre; Ludovica Carbonari; Paolo Sammartino Journal: Gastroenterol Res Pract Date: 2019-05-02 Impact factor: 2.260
Authors: Ruby M van Stein; Christianne A R Lok; Arend G J Aalbers; Ignace H J T de Hingh; Aletta P I Houwink; Herman J Stoevelaar; Gabe S Sonke; Willemien J van Driel Journal: Gynecol Oncol Rep Date: 2022-02-26
Authors: Michelle V Dietz; Job P van Kooten; Jeroen L A van Vugt; Alexandra R M Brandt-Kerkhof; Cornelis Verhoef; Eva V E Madsen Journal: Ann Surg Oncol Date: 2022-06-01 Impact factor: 4.339
Authors: Alba Fernández-Candela; Alicia Calero; Luís Sánchez-Guillén; Javier Escrig-Sos; José A Barreras; Francisco López-Rodríguez-Arias; Laura Armañanzas; Ana Murcia; Antonio Arroyo; Francisco Javier Lacueva Journal: Nutrients Date: 2021-06-23 Impact factor: 5.717